Functional Mushrooms for Anxiety: What the Research Shows

Mushrooms & Mental Health

43.8% anxiety reduction

A 2026 double-blind RCT found participants taking a Reishi, Lion's Mane, and Cordyceps blend reported 43.8% lower anxiety scores after 12 weeks, compared to 10.1% in the placebo group.

Hisamuddin et al., Brain and Behavior, 2026

24%

lower odds of depression in mushroom consumers in a 24,699-person NHANES study

3 species

Reishi, Lion's Mane, and Cordyceps each have published human or animal evidence

4 pathways

serotonergic, oxidative, neuroinflammatory, gut-brain axis: all active in mushroom anxiety research

Hisamuddin et al., Brain and Behavior, 2026

View as image ↗

In a study of 24,699 Americans drawn from the National Health and Nutrition Examination Survey, people who consumed mushrooms regularly had roughly 24% lower odds of depression compared to non-consumers, even after researchers adjusted for diet, income, exercise, and other lifestyle factors.^[5] This wasn't a study about medicinal mushrooms specifically. It was ordinary dietary mushroom consumption, and the signal showed up in the population anyway.

That population finding doesn't prove mechanism or establish clinical benefit by itself. But it raises a question worth asking: what does the actual research say when scientists go looking for how functional mushrooms affect anxiety and mood? The answer, as of 2026, is more interesting and more nuanced than most supplement content suggests. This article is an overview of the evidence; for the broader framework of how adaptogenic mushrooms respond to stress, start with the pillar.

Three Species With Human Evidence: A Quick Map Before the Deep Dive

Before the species-by-species breakdown, here's the state of the evidence in plain terms:

Lion's Mane (Hericium erinaceus): Human RCT evidence from 2010 to 2025. Works through nerve growth factor (NGF) induction and hippocampal neurogenesis. A 2025 systematic review covered 5 RCTs specifically. The strongest evidence base of the three.

Reishi (Ganoderma lucidum): Two dedicated human trials in general populations, plus a 2024 college student RCT. Works through GABAergic modulation (similar pathway to anti-anxiety medications) and gut microbiota changes that drive serotonin production. Evidence base is smaller but mechanistically more distinctive.

Cordyceps (Cordyceps militaris): Strong antidepressant signal in animal models, different signaling pathway from the other two. No dedicated human anxiety RCT yet. Included in the 2026 blend trial as one of three active components.

These aren't interchangeable. They work differently, the evidence behind them differs in quality, and combining them (as the 2026 Hisamuddin trial did) may produce effects that outperform any single species.^[4]

Lion's Mane: From a 2010 Landmark RCT to a 2025 Systematic Review

The modern research on Lion's Mane and anxiety starts with Nagano and colleagues in 2010.^[6] Their double-blind crossover trial gave 30 menopausal women either Hericium erinaceus supplement or placebo for four weeks, then crossed them over to the opposite condition. Anxiety and depression scores on a validated scale fell significantly in the Lion's Mane group compared to placebo. Irritability decreased and concentration improved. This trial's specific population (menopausal women) limits how broadly you can apply the finding, but the study design was solid and the result has replicated.

Vigna and colleagues followed in 2019 with a larger trial: 77 overweight and obese adults who took either Lion's Mane with whey protein or a whey-only placebo for eight weeks.^[7] Mood scores on the Beck Depression Inventory improved significantly in the Lion's Mane group. Sleep disorders improved. Importantly, Vigna's team measured circulating pro-BDNF, a precursor to brain-derived neurotrophic factor, and found it increased in the Lion's Mane group. This was meaningful because it bridged the animal mechanism (Lion's Mane promotes NGF and BDNF in the brain) to actual human biology.

By 2025, Menon and colleagues had enough accumulated evidence to publish a systematic review covering the entire published literature on H. erinaceus as a supplement.^[11] The review catalogued 5 RCTs, 15 laboratory studies, 3 pilot clinical trials, and 1 cohort study. The overall signal for cognitive function and mood was positive. The safety profile was favorable throughout the evidence base, with rare adverse events. The review's conclusion: Lion's Mane is a promising supplement for mood and cognition with a growing body of supportive evidence.

The 2020 review by Chong and colleagues synthesized what that evidence tells us about mechanism.^[12] NGF promotion is the core pathway: Lion's Mane's active compounds (erinacines in the mycelium, hericenones in the fruiting body) stimulate NGF synthesis in the brain. NGF supports the survival and function of neurons in brain regions involved in mood, memory, and anxiety regulation. When Ryu and colleagues blocked neurogenesis pharmacologically in their mouse model, the antidepressant effect disappeared, confirming that neurogenesis is not just correlated with the effect, it's the mechanism. For a deeper look at this NGF pathway and how it relates to anxiety, see our article on Lion's Mane and anxiety: mechanisms and studies.

Reishi: Two Clinical Populations and a Pathway That Looks Like a Sedative

Reishi's anxiety mechanism is distinct from Lion's Mane's. Where Lion's Mane rebuilds neurological resilience through NGF, Reishi modulates the signaling systems that create acute anxiety responses in the first place.

The most mechanistically precise preclinical evidence comes from Socala and colleagues. In their 2015 study, Reishi aqueous mycelial extract produced anxiolytic effects in mice using the elevated plus-maze test, a standard anxiety model. At high doses, the effect was comparable to diazepam. Diazepam is a benzodiazepine that works by enhancing GABA-A receptor activity, the primary inhibitory signaling system in the brain. That Reishi showed comparable anxiolytic effects in the same behavioral test is a meaningful clue about mechanism, though the comparison is preclinical and animal-based, not a head-to-head clinical trial.

The human evidence comes from two distinct clinical populations. Mitra and colleagues published a 2024 RCT testing Reishi supplementation in female college students over 12 weeks.^[9] Psychological stress scores fell significantly in the supplement group compared to placebo, along with improvements in select fitness parameters. This is a healthier, younger population than some earlier Reishi studies, which makes the finding more generalizable. Pazzi and colleagues had earlier found that Reishi supplementation improved depression, anxiety, and quality-of-life scores in women with fibromyalgia compared to an exercise control, representing a different population but a second human data point for mood and anxiety outcomes.^[8]

There's also a second Reishi anxiety pathway that no competitor article currently covers. Yao and colleagues demonstrated in 2021 that Reishi modulates the gut microbiome, specifically increasing populations of Lactobacillus and Bifidobacterium. This change in gut bacteria composition drove increases in serotonin production, reducing sleep latency in mice. This gut-brain-serotonin pathway is separate from the direct GABAergic mechanism, suggesting Reishi may affect anxiety through complementary routes. For the HPA axis dimension of Reishi's stress response, see our article on how mushrooms regulate cortisol and the HPA axis. And for an in-depth review of Reishi's stress evidence specifically, see Reishi for stress.

Cordyceps: Antidepressant Effects in Animals, No Human Anxiety Trials Yet

Cordyceps militaris rounds out the three species in the 2026 blend trial, but it's the one with the least anxiety-specific human evidence.

Lin and colleagues published a 2021 animal study showing Cordyceps militaris water extract produced antidepressant-like effects in chronically stressed mice.^[10] The mechanism was distinct from both Reishi and Lion's Mane: ROCK2/PTEN/Akt signaling, a pathway involved in neuronal survival and inflammatory regulation. The behavioral results were clear. The mechanism was specific. But it was in mice, not people, and the study focused on depression-like behavior rather than anxiety specifically.

No published human RCT has tested Cordyceps alone for anxiety in a general population. The contribution of Cordyceps to the Hisamuddin 2026 blend's 43.8% anxiety reduction is impossible to separate from the Reishi and Lion's Mane in that trial's design. Cordyceps has a strong evidence base for other outcomes (fatigue, athletic performance, kidney function) where human trials exist. For anxiety specifically, it's a preclinical signal waiting for clinical validation.

Four Mechanisms: Why Functional Mushrooms Affect Anxiety at All

The research on which specific compounds produce which specific effects has matured enough to offer a coherent mechanistic picture. Lazur and colleagues synthesized the available evidence in a 2023 review and identified four primary pathways through which medicinal mushrooms affect anxiety and depression.^[2]

The first pathway is serotonergic modulation. Several medicinal mushrooms contain compounds that influence serotonin synthesis or receptor activity. Reishi's gut microbiome effects (driving Lactobacillus/Bifidobacterium increases that produce more serotonin) are one example. Cordyceps' effects on the serotonergic system in animal models are another.

The second pathway is oxidative stress reduction. High oxidative stress in the brain is associated with anxiety and depression in a substantial body of research. Mushrooms are rich in ergothioneine, a powerful antioxidant synthesized almost exclusively by fungi. Ergothioneine accumulates in the brain and nervous system and protects against oxidative damage to neurons. Ba and colleagues proposed ergothioneine as the primary mediating compound in the NHANES depression association. This is likely one mechanism by which even ordinary dietary mushroom consumption produces population-level mood effects.

The third pathway is neuroinflammation suppression. Chronic neuroinflammation is now established as a driver of anxiety and depression. Beta-glucans from mushroom cell walls, particularly from Reishi and Lion's Mane, modulate macrophage and microglial activity in ways that reduce neuroinflammatory signaling. This is a relatively downstream effect from the immune-modulating properties that medicinal mushrooms are better known for.

The fourth pathway is gut-brain axis regulation. The gut microbiome communicates directly with the brain via the vagus nerve and through metabolites that cross the blood-brain barrier. Mushroom polysaccharides act as prebiotics, selectively feeding bacterial populations that produce anxiety-reducing neurotransmitters and anti-inflammatory short-chain fatty acids. Reishi's gut microbiome mechanism (Yao 2021) is the clearest example, but this pathway is relevant across multiple species.

Understanding these four pathways helps explain why mushroom blends might outperform single-species approaches: different species are stronger in different pathways, and combining them activates all four simultaneously. For more on how this works at the population level, see our article on whether daily mushroom consumption improves mental health.

The 2026 Blend Trial: 43.8% vs. 10.1% for Placebo

Hisamuddin and colleagues published what is currently the strongest human evidence for functional mushrooms and anxiety in 2026.^[4] Their double-blind, randomized, placebo-controlled trial tested a Reishi, Lion's Mane, and Cordyceps blend over 12 weeks. Participants took either the mushroom blend or a placebo.

At 12 weeks, the mushroom blend group reported 43.8% lower anxiety scores compared to their baseline. The placebo group reported 10.1% lower scores. The gap between those two numbers represents a treatment effect that is both statistically and clinically meaningful. The trial also showed significant improvements in stress and sleep quality in the blend group.

Several things make this study notable beyond its primary result. First, it uses a blend, not a single species. The 43.8% figure can't be attributed to any one mushroom alone. Second, the study appeared in Brain and Behavior, a peer-reviewed journal in the neuroscience space, not a nutrition or food science journal. Third, it was published in 2026, meaning it incorporates formulations and dosing informed by the entire preceding literature.

The honest limitation: this is one trial with one specific blend. The sample size, exact composition, and dosing details matter for replicability. The result is compelling and directionally consistent with the preceding literature. It's not yet the definitive word, but it's the most clinically actionable evidence in this category to date.

For a detailed comparison of mushroom evidence against prescription anti-anxiety options, see our article on mushrooms vs. anti-anxiety medications.

What the Population Data and the Top Review Say

The Ba 2021 NHANES analysis covered 24,699 Americans and found that mushroom consumers had roughly 24% lower odds of depression on a validated screening scale, after controlling for major confounders.^[5] The association held across different demographic subgroups and was proposed to operate through ergothioneine. The study can't prove causation: people who eat more mushrooms may have other dietary or lifestyle habits that explain the association. But the signal is large, consistent, and appeared in a well-powered dataset.

Cha and colleagues synthesized the accumulated evidence in a 2024 review published in Neuroscience and Biobehavioral Reviews, the highest-impact journal in this research area.^[1] Their conclusion: mushroom consumption is associated with improved mood and reduced anxiety across the lifespan, from young adults through older age. The strongest evidence applies to H. erinaceus and G. lucidum. The review's primary limitation call: standardized dosing protocols across trials are needed before definitive conclusions can be drawn.

The 2022 review by Fijałkowska and colleagues covered edible mushrooms as a dietary approach to major depressive disorder and noted a pattern that applies equally to anxiety research: strong and consistent preclinical signals, equivocal but directionally positive clinical results, and a clear need for larger trials with standardized methods.^[3] That honest assessment from a peer-reviewed systematic review is more useful than any supplement brand's claim of certainty.

The trajectory of the evidence is clear. From Nagano's 30-person crossover trial in 2010 to Hisamuddin's blend RCT in 2026, each new study has added to a consistent and growing body of evidence. The 2026 trial is the largest and most recent. It doesn't close the book on functional mushrooms and anxiety, but it gives the category the kind of rigorous human RCT data it previously lacked. What comes next is the clinical trials that test individual species at standardized doses in diagnosed anxiety populations. Those don't exist yet. The preliminary picture is positive.

The Bottom Line

Three functional mushroom species have published human evidence for anxiety and mood outcomes: Lion's Mane (strongest trail, multiple RCTs, 2010-2025), Reishi (two clinical populations, two distinct mechanisms), and Cordyceps (animal evidence only for anxiety specifically). A 2026 double-blind RCT combining all three produced 43.8% anxiety reduction versus 10.1% for placebo over 12 weeks. The evidence is promising and building, but large-scale clinical trials in diagnosed anxiety populations are still needed before this category reaches the standard required for clinical recommendation.

Frequently Asked Questions

What mushrooms are good for anxiety?

Three functional mushrooms have the most evidence for anxiety: Lion's Mane (Hericium erinaceus), with multiple human RCTs showing reduced anxiety and depression scores; Reishi (Ganoderma lucidum), with clinical trial evidence and two distinct anxiety-relevant mechanisms (GABAergic modulation and gut-serotonin production); and Cordyceps, which shows antidepressant effects in animal models but lacks dedicated human anxiety trials. A 2026 RCT combining all three produced 43.8% anxiety reduction versus 10.1% placebo (Hisamuddin et al.).

Do functional mushrooms actually work for anxiety?

The evidence shows a consistent positive signal, but what "work" means matters. Human trial evidence exists for Lion's Mane (reduced anxiety scores in multiple RCTs) and Reishi (reduced stress in a 2024 college student trial; improved mood in fibromyalgia). A 2026 blend RCT showed 43.8% anxiety score reduction. No functional mushroom has been tested in large trials with diagnosed anxiety disorder patients. The research supports a real effect on mood and stress-related outcomes; whether it translates to clinical anxiety disorders requires more study.

Which mushroom is best for anxiety and depression?

Lion's Mane has the most human RCT evidence specifically targeting anxiety and depression, with the Nagano 2010 RCT as the landmark study and a 2025 systematic review of 5 RCTs confirming a positive signal. Reishi is the strongest candidate for anxiety specifically because of its GABAergic mechanism and two clinical trials. A combination approach appears to outperform single species: a 2026 blend trial with Reishi, Lion's Mane, and Cordyceps produced stronger anxiety reduction than any individual species has shown in isolation.

Can functional mushrooms help anxiety without being psychedelic?

Yes. Functional mushrooms like Reishi, Lion's Mane, and Cordyceps have no psychedelic activity. They work through entirely different mechanisms than psilocybin-containing mushrooms: Reishi modulates GABA signaling (the same system as benzodiazepines) and gut microbiota; Lion's Mane promotes nerve growth factor and hippocampal neurogenesis; Cordyceps affects inflammatory and neuronal signaling pathways. None of these mechanisms involves serotonin 2A receptor agonism, which is how psilocybin produces altered perception. For more on this distinction, see functional mushrooms for anxiety without psilocybin.

How long do functional mushrooms take to work for anxiety?

Based on available trial data: human RCTs showing anxiety and mood effects have used durations of 4 weeks (Nagano 2010), 8 weeks (Vigna 2019), and 12 weeks (Mitra 2024, Hisamuddin 2026). Effects generally appear after several weeks of consistent supplementation, not acutely. One exception: a 2025 Surendran RCT demonstrated acute same-day mood improvement from a single dose of standardized Lion's Mane extract, suggesting some effects may onset faster than previously thought. The 4-12 week range is the most common timeframe for sustained anxiety-relevant outcomes in published trials.

Do adaptogenic mushrooms actually work?

For anxiety and stress specifically, the evidence is positive and growing. A 2024 lifespan review in Neuroscience and Biobehavioral Reviews found mushroom consumption associated with improved mood and reduced anxiety across age groups, with the strongest evidence for Lion's Mane and Reishi (Cha et al.). A 2026 double-blind RCT with a three-mushroom blend showed 43.8% anxiety reduction vs. 10.1% placebo. The evidence meets the threshold for "plausible and consistent." It doesn't yet meet the threshold for "proven in large clinical trials with diagnosed patients." That distinction matters for setting expectations.

Sources & References

1. 1RTHM-00868·Cha, Sara et al. (2024). “A review of the effects of mushrooms on mood and neurocognitive health across the lifespan..” Neuroscience and biobehavioral reviews.Study breakdown →PubMed →↩
2. 2RTHM-00837·Lazur, Jan et al. (2023). “Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review..” Antioxidants (Basel.Study breakdown →PubMed →↩
3. 3RTHM-01514·Fijałkowska, Agata et al. (2022). “Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder..” Foods (Basel.Study breakdown →PubMed →↩
4. 4RTHM-00959·Hisamuddin, Ahmad Safiyyu'd-Din et al. (2026). “Adaptogenic Effects of Mushroom Blend Supplementation on Stress, Fatigue, and Sleep: A Randomised, Double-Blind, and Placebo-Controlled Trial..” Brain and behavior.Study breakdown →PubMed →↩
5. 5RTHM-00672·Ba, Djibril M et al. (2021). “Mushroom intake and depression: A population-based study using data from the US National Health and Nutrition Examination Survey (NHANES), 2005-2016..” Journal of affective disorders.Study breakdown →PubMed →↩
6. 6RTHM-00194·Nagano, Mayumi et al. (2010). “Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake..” Biomedical research (Tokyo.Study breakdown →PubMed →↩
7. 7RTHM-00590·Vigna, Luisella et al. (2019). “Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers?.” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
8. 8RTHM-00648·Pazzi, Francesco et al. (2020). “Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia..” Healthcare (Basel.Study breakdown →PubMed →↩
9. 9RTHM-00895·Mitra, Sudeep et al. (2024). “Efficacy of Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Agaricomycetes) Supplementation on Psychological Stress and Selective Fitness Profile Parameters in Female College Students in West Bengal, India..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
10. 10RTHM-00700·Lin, Yu-En et al. (2021). “Antidepressant-like effects of water extract of Cordyceps militaris (Linn.) Link by modulation of ROCK2/PTEN/Akt signaling in an unpredictable chronic mild stress-induced animal model..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
11. 11RTHM-00943·Menon, Arya et al. (2025). “Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review..” Frontiers in nutrition.Study breakdown →PubMed →↩
12. 12RTHM-01044·Chong, Pit Shan et al. (2019). “Therapeutic Potential of Hericium erinaceus for Depressive Disorder..” International journal of molecular sciences.Study breakdown →PubMed →↩